Chris Schott
Stock Analyst at JP Morgan
(3.54)
# 746
Out of 4,827 analysts
127
Total ratings
55.42%
Success rate
2.08%
Average return
Main Sectors:
Stocks Rated by Chris Schott
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BIIB Biogen | Maintains: Neutral | $185 → $175 | $118.39 | +47.82% | 4 | May 5, 2025 | |
| REGN Regeneron Pharmaceuticals | Maintains: Overweight | $1,100 → $1,000 | $547.67 | +82.59% | 6 | Mar 31, 2025 | |
| GILD Gilead Sciences | Maintains: Overweight | $120 → $130 | $98.16 | +32.44% | 5 | Mar 27, 2025 | |
| AMRX Amneal Pharmaceuticals | Upgrades: Overweight | $9 → $12 | $7.46 | +60.86% | 2 | Feb 24, 2025 | |
| ABBV AbbVie | Maintains: Overweight | $210 → $200 | $185.58 | +7.77% | 2 | Nov 13, 2024 | |
| TEVA Teva Pharmaceutical Industries | Maintains: Neutral | $16 → $18 | $18.07 | -0.39% | 15 | Oct 21, 2024 | |
| IDXX IDEXX Laboratories | Maintains: Overweight | $630 → $575 | $489.98 | +17.35% | 7 | Oct 11, 2024 | |
| ZTS Zoetis | Maintains: Overweight | $225 → $230 | $161.69 | +42.25% | 2 | Oct 11, 2024 | |
| LLY Eli Lilly and Company | Maintains: Overweight | $1,050 → $1,100 | $751.45 | +46.38% | 20 | Sep 13, 2024 | |
| OGN Organon & Co. | Downgrades: Underweight | $18 → $20 | $9.02 | +121.73% | 2 | Sep 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $48 → $41 | $26.80 | +52.99% | 11 | Feb 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $45 → $42 | $33.10 | +26.89% | 4 | Feb 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Neutral | $270 | $272.05 | -0.75% | 1 | Oct 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $36 → $34 | $22.97 | +48.02% | 10 | Oct 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $120 → $125 | $77.65 | +60.98% | 7 | Feb 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $13 → $14 | $9.09 | +54.02% | 2 | Nov 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $13 → $11 | $0.99 | +1,008.54% | 4 | Nov 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $24 → $20 | $12.28 | +62.87% | 3 | Oct 17, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $4.70 | - | 4 | Jul 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $74 → $78 | $46.88 | +66.38% | 7 | Oct 16, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $700 → $950 | $3.43 | +27,596.79% | 4 | May 27, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $1.40 | - | 2 | May 19, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $45 → $50 | $24.91 | +100.72% | 3 | Nov 2, 2018 |
Biogen
May 5, 2025
Maintains: Neutral
Price Target: $185 → $175
Current: $118.39
Upside: +47.82%
Regeneron Pharmaceuticals
Mar 31, 2025
Maintains: Overweight
Price Target: $1,100 → $1,000
Current: $547.67
Upside: +82.59%
Gilead Sciences
Mar 27, 2025
Maintains: Overweight
Price Target: $120 → $130
Current: $98.16
Upside: +32.44%
Amneal Pharmaceuticals
Feb 24, 2025
Upgrades: Overweight
Price Target: $9 → $12
Current: $7.46
Upside: +60.86%
AbbVie
Nov 13, 2024
Maintains: Overweight
Price Target: $210 → $200
Current: $185.58
Upside: +7.77%
Teva Pharmaceutical Industries
Oct 21, 2024
Maintains: Neutral
Price Target: $16 → $18
Current: $18.07
Upside: -0.39%
IDEXX Laboratories
Oct 11, 2024
Maintains: Overweight
Price Target: $630 → $575
Current: $489.98
Upside: +17.35%
Zoetis
Oct 11, 2024
Maintains: Overweight
Price Target: $225 → $230
Current: $161.69
Upside: +42.25%
Eli Lilly and Company
Sep 13, 2024
Maintains: Overweight
Price Target: $1,050 → $1,100
Current: $751.45
Upside: +46.38%
Organon & Co.
Sep 6, 2024
Downgrades: Underweight
Price Target: $18 → $20
Current: $9.02
Upside: +121.73%
Feb 28, 2024
Maintains: Overweight
Price Target: $48 → $41
Current: $26.80
Upside: +52.99%
Feb 20, 2024
Maintains: Overweight
Price Target: $45 → $42
Current: $33.10
Upside: +26.89%
Oct 20, 2023
Reinstates: Neutral
Price Target: $270
Current: $272.05
Upside: -0.75%
Oct 16, 2023
Maintains: Neutral
Price Target: $36 → $34
Current: $22.97
Upside: +48.02%
Feb 23, 2023
Maintains: Overweight
Price Target: $120 → $125
Current: $77.65
Upside: +60.98%
Nov 15, 2022
Maintains: Neutral
Price Target: $13 → $14
Current: $9.09
Upside: +54.02%
Nov 14, 2022
Maintains: Neutral
Price Target: $13 → $11
Current: $0.99
Upside: +1,008.54%
Oct 17, 2022
Maintains: Neutral
Price Target: $24 → $20
Current: $12.28
Upside: +62.87%
Jul 29, 2022
Downgrades: Neutral
Price Target: n/a
Current: $4.70
Upside: -
Oct 16, 2020
Maintains: Overweight
Price Target: $74 → $78
Current: $46.88
Upside: +66.38%
May 27, 2020
Maintains: Overweight
Price Target: $700 → $950
Current: $3.43
Upside: +27,596.79%
May 19, 2020
Downgrades: Neutral
Price Target: n/a
Current: $1.40
Upside: -
Nov 2, 2018
Maintains: Neutral
Price Target: $45 → $50
Current: $24.91
Upside: +100.72%